Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

14 May 2015

Abstract excerpt

// Marie-Magdelaine Coudé 1,2,* , Thorsten Braun 1,3,* , Jeannig Berrou 1 , Mélanie Dupont 1 , Sibyl Bertrand 1 , Aline Masse 1 , Emmanuel Raffoux 1,4 , Raphaël Itzykson 1,4 , Marc Delord 5 , Maria E. Riveiro 6 , Patrice Herait 7 , André Baruchel 1,8 , Hervé Dombret 1,4 and Claude Gardin 1,3 1 Laboratoire de Transfert des Leucémies, Institut Universitaire d’Hématologie, University Paris VII, Paris, France 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25989842
DOI: 10.18632/oncotarget.4131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cellsPMID 25989842Read ↗

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute LeukemiaSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'Undruggable' Myc-pathway GenesSemantic proximity Read ↗

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemiaSemantic proximity Read ↗

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemiaSemantic proximity Read ↗

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsSemantic proximity Read ↗

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.